目的 探討注射用地塞米松磷酸鈉聯(lián)合長(zhǎng)春西汀注射液和胞磷膽堿鈉氯化鈉注射液治療突發(fā)性耳聾的臨床療效。方法 選取2016年5月-2017年5月海安縣醫(yī)院收治的突發(fā)性耳聾患者112例為研究對(duì)象，按照數(shù)表法將患者隨機(jī)分為對(duì)照組和治療組，每組各56例。對(duì)照組靜脈滴注胞磷膽堿鈉氯化鈉注射液，0.5 g加入到0.9%氯化鈉溶液250 mL中，1次/d；且對(duì)照組緩慢靜脈滴注長(zhǎng)春西汀注射液，30 mg加入到0.9%氯化鈉溶液500 mL中，1次/d。治療組在對(duì)照組基礎(chǔ)上靜脈滴注注射用地塞米松磷酸鈉，10 mg加入到5%葡萄糖溶液250 mL中，1次/d，3 d后劑量調(diào)整為5 mg/次。兩組患者均連續(xù)治療7~10 d。觀察兩組的臨床療效，比較兩組的聽(tīng)力指標(biāo)，眩暈、耳鳴發(fā)生率和血液流變學(xué)。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為85.71%、96.43%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組平均純音聽(tīng)閾、低頻區(qū)聽(tīng)閾和高頻區(qū)聽(tīng)閾均顯著下降，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組耳鳴和眩暈的發(fā)生率顯著下降，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組全血高切黏度、全血低切黏度和血漿黏度均顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 注射用地塞米松磷酸鈉聯(lián)合長(zhǎng)春西汀注射液和胞磷膽堿鈉氯化鈉注射液治療突發(fā)性耳聾具有較好的臨床療效，改善臨床癥狀，調(diào)節(jié)血液流變學(xué)指標(biāo)，安全性較好，具有一定臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Dexamethasone Sodium Phosphate for injection combined with Vinpocetine Injection and Citicoline Sodium and Sodium Chloride Injection in treatment of sudden deafness. Methods Patients (112 cases) with sudden deafness in Hai'an County People's Hospital from May 2016 to May 2017 were randomly divided into control and treatment groups, and each group had 56 cases. Patients in the control group were iv administered with Citicoline Sodium and Sodium Chloride Injection, 0.5 g added into normal saline 250 mL, once daily. And patients in the control group were also iv administered with Vinpocetine Injection, 30 mg added into normal saline 500 mL, once daily. Patients in the treatment group were iv administered with Dexamethasone Sodium Phosphate for injection on the basis of the control group, 10 mg added into 5% glucose solution 250 mL, once daily, and the dose was adjusted to 5 mg/time after 3 d. Patients in two groups were treated for 7-10 d. After treatment, the clinical efficacies were evaluated, and hearing indexes, the incidence rates of vertigo and tinnitus, and hemorheology in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 85.71% and 96.43%, respectively, and there was difference between two groups (P<0.05). After treatment, the average pure tone threshold, low frequency threshold, and high frequency region threshold in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the incidence of tinnitus and vertigo in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the whole blood high shear viscosity, whole blood low shear viscosity, and plasma viscosity in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Dexamethasone Sodium Phosphate for injection combined with Vinpocetine Injection and Citicoline Sodium and Sodium Chloride Injection has clinical curative effect in treatment of sudden deafness, can improve clinical symptoms, and can regulate blood rheology indexes, with good safety, which has a certain clinical application value.